Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma is organized by i3 Health.

Dates Available:
02/10/2023 - 02/09/2024

Statement of Need:
Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al., 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al., 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been approved for RCC in recent years; therefore, it is important for the cancer care team to update their knowledge of RCC pathophysiology and the benefits and risks of novel therapies. In this activity presented at the Society of Government Service Urologists James C. Kimbrough Urological Seminar, Eric Jonasch, MD, Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center, imparts expert perspectives and details the latest treatment options for advanced RCC.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Discuss the immunogenicity of RCC and the implications for the treatment of advanced disease
  • Assess criteria for risk stratification of patients with advanced RCC
  • Evaluate recent clinical trial findings on novel treatment strategies for advanced RCC with checkpoint inhibitors and VEGFR-directed therapies

Eric Jonasch, MD
Professor of Medicine
University of Texas
MD Anderson Cancer Center


PhysicianNursingPhysician AssistantOncologistsUrologists




For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:

  • The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
  • The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.


Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
1 AMA PRA Category 1 Credit™ ...
More actions
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
1 AMA PRA Category 1 Credit™ ...
More actions
Hitting the Target in HER2-Positive Metastatic Colorectal Cancer
Jun 13, 2023 - Jun 12, 2024 | Webcast
Colon and Rectal Surgery
1 AMA PRA Category 1 Credit™ ...
More actions